Trial Profile
A phase IIIa trial of INP-102 in patients with Alzheimer's disease
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Sep 2022
Price :
$35
*
At a glance
- Drugs Insulin (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- 22 Aug 2018 According to an Impel NeuroPharma media release, a series of trials of INP102 (POD-insulin) for Alzheimer's disease (including this trial) in currently funded by the NIH.
- 15 Oct 2015 New trial record